This is consistent with work showing that BRD4 and β-catenin may be genetically abrogated in murine HSCs with only modest effects during steady state hematopoiesis and without inducing bone marrow failure [83, 84]. This evidence concerns the gene BRD4 and Bone marrow hypocellularity.